【Healthkoreanews】AstraZeneca Korea has concluded an agreement on the co-promotion of Nexium with Daewoong co. on Dec. 4.
By that agreement, AstraZeneca Korea can sell Nexium to the major general hospitals, and Daewoong co. can sell it to other hospitals and clinics.
Nexium is an effective treatment for patients with gastroesophageal reflux disease (GERD).
Lee jong-wook, president of Daewoong co. said, “This agreement will serve as a momentum of synergy effect for AstraZeneca Korea and Daewoong. <헬스코리아뉴스>